Disclaimer: The Views/Opinions expressed and/or opinions provided in Videos and other content on MedEnrich Website are those of respective speakers. They do not purport to reflect the opinion or views of Dr.Reddy’s Laboratories Limited or its affiliates (collectively Dr.Reddy’s)in any manner whatsoever and accordingly ,Dr.Reddys does not recommend , endorse or make any representation about the veracity and appropriateness of the views ,opinions/ information on MedEnrich website. Content on MedEnrich website may discuss uses and dosage for therapeutic product that may not have been approved in by the relevant regulatory agencies in your country. Dr.Reddy’s does not support , endorse or encourage any off-label use. Please refer to approved label before prescribing.
Duration of trastuzumab in patients with Her2 positive Metastatic Breast Cancer in prolonged remission
Breast Cancer Published 1 year ago
Content
Breast Cancer
2m 3s
Immunotherapy in Breast Cancer : Where Are We ?
Published 30 Aug 2022
Immunotherapy has redefined the treatment of Triple Negative Breast Cancer. Pembrolizumab was approved in the recent past for both high risk early-stage Triple Negative Breast cancer and Metastatic Triple Negative Breast Cancer patients in combination with chemotherapy. Antibody Drug Conjugates can be promising treatment options in future with Immunotherapy as backbone. There is an ever-increasing interest to identify Biomarkers for response as well as toxicity of Immunotherapy. In addition to mTNBC, the role of Immunotherapy is being explored in Hormone Receptor Positive and Her-2 Positive MBC.
